Phathom Pharmaceuticals (PHAT) was upgraded by Barclays PLC from "equal weight" to "overweight". They now have a $18.00 price target on the stock, up from $16.00.
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]